In this episode Dr. Slavin welcomes Dr. Judy Garber, Professor of Medicine at Harvard Medical School, Chief of Division of Cancer Genetics and Prevention at the Dana Farber Institute, and Susan F. Smith Chair. Together, they discuss the OlympiA study and outcomes that have influenced industry guidelines.
05/23/22 • 23 min
Inside the GENOME - What we’ve learned from the OlympiA study, with Dr. Judy Garber
Transcript
[music]
0:00:11.7 Thomas Slavin: Hi, I'm Dr. Thomas Slavin, Chief Medical Officer for Myriad Genetics. Welcome to Inside The Genome. Hi everyone, welcome back to the podcast. Today, we're delighted to have Dr. Judy Garber, she is the Susan F. Smith chair, and chief of the Division for Cancer Genetics and Prevention at the Dana-Farber Institute. She is also a professor of medicine at Harvard Medical School. Thank you for coming on the podcast today, Dr. Garber.
Generate a badge
Get a badge for your website that links back to this episode
<a href="https://goodpods.com/podcasts/inside-the-genome-214550/what-weve-learned-from-the-olympia-study-with-dr-judy-garber-24032480"> <img src="https://storage.googleapis.com/goodpods-images-bucket/badges/generic-badge-1.svg" alt="listen to what we’ve learned from the olympia study, with dr. judy garber on goodpods" style="width: 225px" /> </a>
Copy